Liver enzyme effects of medicinal cannabis in advanced cancer: a substudy of two randomised trials
- 21 December 2025
- journal article
- Published by BMJ in BMJ Supportive & Palliative Care
Abstract
Objectives: This substudy investigated whether medicinal cannabis causes an elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in patients with advanced malignancy and determined whether different cannabis formulations (cannabidiol (CBD) alone vs tetrahydrocannabinol (THC)/CBD combination) had differing effects on enzyme levels. Methods: This analysis used data from two multicentre, randomised, placebo-controlled trials of escalating doses of CBD (MedCan1) or THC/CBD (MedCan2), including 287 patients with advanced cancer. Participants received escalating doses of CBD, THC/CBD or placebo. ALT and AST levels were measured at baseline, day 14 and day 28. Results: Medicinal cannabis did not cause elevation of ALT or AST in patients with advanced malignancy at the doses studied (up to 600 mg CBD/day). No clinically meaningful differences in liver enzyme levels were observed between CBD-only and CBD/THC combination products. Furthermore, no patients in the cannabis groups exceeded the predefined thresholds of 3× upper limit of normal (ULN) (or 5× ULN in those with liver metastases) for ALT or AST. Conclusions: In patients with advanced malignancy enrolled in two clinical trials, medicinal cannabis products did not have a significant adverse impact on ALT or AST levels during the first 4 weeks of use at the doses studied.Keywords
This publication has 11 references indexed in Scilit:
- A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care.Journal of Clinical Oncology, 2024
- Cannabidiol‐associated hepatotoxicity: A systematic review and meta‐analysisJournal of Internal Medicine, 2023
- Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)Journal of Clinical Oncology, 2023
- Cannabis in Palliative Care: A Systematic Review of Current EvidenceJournal of Pain and Symptom Management, 2022
- Evaluating the impacts of cannabis legalization: The International Cannabis Policy StudyInternational Journal of Drug Policy, 2020
- Pharmacology and drug interactions of cannabinoidsEpileptic Disorders, 2020
- Is cannabidiol hepatotoxic or hepatoprotective: A reviewToxicology Research and Application, 2020
- Drug-induced liver injuryNature Reviews Disease Primers, 2019
- Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trialsCancer, 2012
- Part I: Liver function in oncology: biochemistry and beyondThe Lancet Oncology, 2008